Evidence map›Paper›PMID 21811642›Full record

ArticlePLoS neglected tropical diseases2011

Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.

Fred S Sarfo, Fabien Le Chevalier, N'Guetta Aka, Richard O Phillips, Yaw Amoako, Ivo G Boneca, Pascal Lenormand, Mireille Dosso, Mark Wansbrough-Jones, Romain Veyron-Churlet and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Conditions for Handling and Optimal Storage of Mycolactone.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  9. Natural antioxidants attenuate mycolactone toxicity to RAW 264.7 macrophages.Experimental biology and medicine (Maywood, N.J.) · 2021
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Fred S SarfoKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Fabien Le Chevalier
N'Guetta Aka
Richard O Phillips
Yaw Amoako
Ivo G Boneca
Pascal Lenormand
Mireille Dosso
Mark Wansbrough-Jones
Romain Veyron-Churlet
Laure Guenin-Macé
Caroline Demangel
Institut Pasteur · FRKomfo Anokye Teaching Hospital · GHInstitut Pasteur de Côte d'Ivoire · CIInserm · FRSt George's, University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMycobacterium ulcerans, the causative agent of Buruli ulcer (BU), is unique among human pathogens in its capacity to produce a polyketide-derived macrolide called mycolactone, making this molecule an attractive candidate target for diagnosis and disease monitoring. Whether mycolactone diffuses from ulcerated lesions in clinically accessible samples and is modulated by antibiotic therapy remained to be established. METHODOLOGY/PRINCIPAL FINDING: Peripheral blood and ulcer exudates were sampled from patients at various stages of antibiotic therapy in Ghana and Ivory Coast. Total lipids were extracted from serum, white cell pellets and ulcer exudates with organic solvents. The presence of mycolactone in these extracts was then analyzed by a recently published, field-friendly method using thin layer chromatography and fluorescence detection. This approach did not allow us to detect mycolactone accurately, because of a high background due to co-extracted human lipids. We thus used a previously established approach based on high performance liquid chromatography coupled to mass spectrometry. By this means, we could identify structurally intact mycolactone in ulcer exudates and serum of patients, and evaluate the impact of antibiotic treatment on the concentration of mycolactone. CONCLUSIONS/SIGNIFICANCE: Our study provides the proof of concept that assays based on mycolactone detection in serum and ulcer exudates can form the basis of BU diagnostic tests. However, the identification of mycolactone required a technology that is not compatible with field conditions and point-of-care assays for mycolactone detection remain to be worked out. Notably, we found mycolactone in ulcer exudates harvested at the end of antibiotic therapy, suggesting that the toxin is eliminated by BU patients at a slow rate. Our results also indicated that mycolactone titres in the serum may reflect a positive response to antibiotics, a possibility that it will be interesting to examine further through longitudinal studies.

Indexed as

AdolescentAdultAnti-Bacterial AgentsBacterial ToxinsBiomarkersBuruli UlcerChromatography, High Pressure LiquidChromatography, Thin LayerExudates and TransudatesFemaleHumansLeukocytes, MononuclearMacrolidesMaleMass SpectrometryMycobacterium ulceransAnti-Bacterial AgentsBacterial ToxinsBiomarkersMacrolidesmycolactone

Identifiers

PMID21811642
PMCPMC3139662
OpenAlexW2057339612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.